Romiplostim is effective for eltrombopag-refractory aplastic anemia: results of a retrospective study
| Autor: | Hiromitsu Iizuka, Yoshimasa Kamoda, Masako Hirao, Michiko Kida, Kensuke Usuki, Masataka Ise |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Recombinant Fusion Proteins Eltrombopag Receptors Fc Benzoates chemistry.chemical_compound Refractory Internal medicine medicine Humans Prospective Studies Aplastic anemia Adverse effect Thrombopoietin Aged Retrospective Studies Aged 80 and over Univariate analysis Romiplostim business.industry Drug Substitution Platelet Count Anemia Refractory Anemia Aplastic Retrospective cohort study Hematology Drug Tolerance Middle Aged medicine.disease Hydrazines chemistry Pyrazoles Female business Receptors Thrombopoietin medicine.drug Follow-Up Studies |
| Zdroj: | International journal of hematology. 112(6) |
| ISSN: | 1865-3774 |
| Popis: | Eltrombopag (EPAG) and romiplostim (ROM), thrombopoietin receptor-agonists with demonstrated efficacy against aplastic anemia (AA) in prospective controlled studies, were authorized in Japan for use in adults with aplastic anemia in 2017 and 2019, respectively. So far, no data are available on the potential contribution of switching from ROM to EPAG or vice versa in terms of efficacy or tolerance. Efficacies and tolerance profiles of ten patients, who failed to respond to the maximum dose of EPAG and then switched to ROM, were evaluated. All ten patients received a maximum dose of ROM (20 μg/kg/week). At a median follow-up of twelve months, seven of ten patients (70%) had achieved either neutrophil, erythroid, or platelet response, including one complete response. No patients showed platelet count fluctuations that were reported during ROM treatment for immune thrombocytopenia. In univariate analysis of the relationship between efficacy and demographics, the response had a correlation with neither factors. None of the patients stopped the ROM treatment because of adverse events. Although a larger number of patients and a longer follow-up period are needed to confirm our findings, our results show the efficacy of ROM in patients with EPAG-refractory AA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink